S&P 500   3,278.47 (+1.07%)
DOW   28,764.19 (+0.80%)
QQQ   221.46 (+1.54%)
AAPL   316.46 (+2.43%)
FB   218.20 (+1.55%)
MSFT   165.28 (+1.85%)
GOOGL   1,452.37 (+1.44%)
CGC   23.20 (+7.61%)
NVDA   247.33 (+2.96%)
BABA   210.07 (+2.24%)
MU   56.44 (+1.86%)
GE   11.74 (+2.62%)
T   38.62 (+0.97%)
ACB   1.93 (+2.12%)
F   8.95 (+0.67%)
NFLX   350.21 (+2.14%)
BAC   33.31 (+1.40%)
DIS   138.24 (+1.72%)
GILD   64.60 (+1.21%)
S&P 500   3,278.47 (+1.07%)
DOW   28,764.19 (+0.80%)
QQQ   221.46 (+1.54%)
AAPL   316.46 (+2.43%)
FB   218.20 (+1.55%)
MSFT   165.28 (+1.85%)
GOOGL   1,452.37 (+1.44%)
CGC   23.20 (+7.61%)
NVDA   247.33 (+2.96%)
BABA   210.07 (+2.24%)
MU   56.44 (+1.86%)
GE   11.74 (+2.62%)
T   38.62 (+0.97%)
ACB   1.93 (+2.12%)
F   8.95 (+0.67%)
NFLX   350.21 (+2.14%)
BAC   33.31 (+1.40%)
DIS   138.24 (+1.72%)
GILD   64.60 (+1.21%)
S&P 500   3,278.47 (+1.07%)
DOW   28,764.19 (+0.80%)
QQQ   221.46 (+1.54%)
AAPL   316.46 (+2.43%)
FB   218.20 (+1.55%)
MSFT   165.28 (+1.85%)
GOOGL   1,452.37 (+1.44%)
CGC   23.20 (+7.61%)
NVDA   247.33 (+2.96%)
BABA   210.07 (+2.24%)
MU   56.44 (+1.86%)
GE   11.74 (+2.62%)
T   38.62 (+0.97%)
ACB   1.93 (+2.12%)
F   8.95 (+0.67%)
NFLX   350.21 (+2.14%)
BAC   33.31 (+1.40%)
DIS   138.24 (+1.72%)
GILD   64.60 (+1.21%)
S&P 500   3,278.47 (+1.07%)
DOW   28,764.19 (+0.80%)
QQQ   221.46 (+1.54%)
AAPL   316.46 (+2.43%)
FB   218.20 (+1.55%)
MSFT   165.28 (+1.85%)
GOOGL   1,452.37 (+1.44%)
CGC   23.20 (+7.61%)
NVDA   247.33 (+2.96%)
BABA   210.07 (+2.24%)
MU   56.44 (+1.86%)
GE   11.74 (+2.62%)
T   38.62 (+0.97%)
ACB   1.93 (+2.12%)
F   8.95 (+0.67%)
NFLX   350.21 (+2.14%)
BAC   33.31 (+1.40%)
DIS   138.24 (+1.72%)
GILD   64.60 (+1.21%)
Log in

NASDAQ:GALT - Galectin Therapeutics Stock Price, Forecast & News

$2.76
-0.01 (-0.36 %)
(As of 01/28/2020 01:50 PM ET)
Today's Range
$2.72
Now: $2.76
$2.76
50-Day Range
$2.76
MA: $2.90
$3.10
52-Week Range
$2.72
Now: $2.76
$6.06
Volume8,510 shs
Average Volume177,373 shs
Market Capitalization$157.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share

Profitability

Net Income$-13,900,000.00

Miscellaneous

Employees6
Market Cap$157.02 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.


Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Tuesday, November, 12th. The company reported ($0.05) EPS for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.03. View Galectin Therapeutics' Earnings History.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Galectin Therapeutics.

What price target have analysts set for GALT?

1 equities research analysts have issued 12-month price objectives for Galectin Therapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they expect Galectin Therapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 298.6% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.

What is the consensus analysts' recommendation for Galectin Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.

Has Galectin Therapeutics been receiving favorable news coverage?

News headlines about GALT stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galectin Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the next several days. View News Stories for Galectin Therapeutics.

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 69)
  • Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
  • Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $2.76.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $157.02 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is http://www.galectintherapeutics.com/.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  591
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel